PredictrPK® ADA Maintenance
Use
This test predicts adalimumab (ADA) levels with alternative dosing strategies and calculates ADA clearance. It measures serum ADA and antibodies-to-ADA (ATA), as well as albumin levels, in IBD patients aged 12 and older. This facilitates tailored dosage adjustments to maintain optimal biologic response and improve patient outcomes.
Special Instructions
Sample collection can occur anytime within the current dosing interval after the patient has been on ADA therapy for at least 8 weeks. Accurate documentation of dosing intervals and history is necessary.
Limitations
This test has not been cleared or approved by the FDA and should be used reflecting that limitation in regulatory approval. Pharmacokinetic variability and inter-individual differences may not be fully captured.
Methodology
Immunoassay (Proteomic Panel)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
Not provided
Container
Serum Separator Tube or Red-Top Tube
Collection Instructions
Collect sample anytime within the ADA injection interval after more than 8 weeks on ADA.
Storage Instructions
Ambient or cold pack. Do not freeze.
Causes for Rejection
Unlabeled specimens; incorrect tube type
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |